

Amendments to the Specification

Please replace the title of the instant application and the title provided at page 1, lines 1 and 2 with the following:

~~METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION~~
ANTIBODIES SPECIFIC FOR NEBR1 AND METHODS OF USE THEREOF

At the indicated page and line numbers, please replace the existing paragraphs with the ones set forth below.

(Page 6, lines 9-20) Figure 5A shows the alignment of NEBR1 with other zinc finger proteins (the sequences are, from top to bottom: SEQ ID NO: 7, amino acids 1-99 of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12). Figures 5B and 5C show the transcriptional activity of KRAB box mutants of NEBR1. HEK293 cells were transfected with 0.6 µg of each pGBD-NEBR1 mutant and either GAL4-Luc or GAL4-TK-Luc (0.3 g) using Lipofectamine Plus. Twenty-four hours after transfection, cells were lysed and subjected to dual-luciferase assay. Control GBD not GBD Box ΔB could suppress GAL4-TK-Luc gene transcription. GBD Box ΔA partially suppressed the gene transcription, however the other mutants suppressed it as potent as full-length NEBR1. Figure 5D shows the spatial relationship between the KRAB box domain and the 13 zinc fingers in NEBR1.